Sagent Pharmaceuticals, Inc. (SGNT) Misses Q1 EPS by 2c

Sagent Pharmaceuticals, Inc. (NASDAQ: SGNT) reported Q1 EPS of ($0.30), $0.02 worse than the analyst estimate of ($0.28). Revenue for the quarter came in at $38.3 million versus the consensus estimate of $42.31 million.

For earnings history and earnings-related data on Sagent Pharmaceuticals, Inc. (SGNT) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• JPMorgan Upgrades Aviva Plc (AV/:LN) (AIVAF) to Overweight
• Birkenstock Holding (BIRK) Misses Q3 EPS by 2c; lifts guidance
• UBS Downgrades FANUC Corp (6954:JP) (FANUY) to Neutral